Novo Nordisk (NVO) Price on Solana

Novo Nordisk is betting on amylin, a pancreatic hormone released alongside insulin that helps regulate hunger and fullness, as the next leg of its obesity business after GLP-1s, according to a CNBC report published October 2. The company's lead amylin asset is CagriSema, which pairs the amylin analogue cagrilintide with semaglutide, the active ingredient in Wegovy and Ozempic. CagriSema has produced greater weight loss than either component alone in clinical studies, and cagrilintide on its own has shown meaningful weight loss in a late-stage trial. Per the report, Novo expects CagriSema to launch in early 2027, with a higher-dose version and standalone cagrilintide following around 2028. Novo is also developing amycretin, a single molecule that acts on both GLP-1 and amylin receptors, as a weekly injection and a daily pill; it posted positive Phase 2 results earlier this year.

Novo is also pitching benefits beyond the number on the scale. A year-long brain-imaging study found CagriSema reduced "food noise" and changed responses to high-calorie foods in brain regions tied to cravings and self-control. Chief scientific officer Martin Holst Lange said the signalling "changed in a way that is associated with improved quality of life." Eli Lilly is chasing the same market: its amylin candidate eloralintide, combined with tirzepatide, produced 23.3% average weight loss over 48 weeks at the top dose in a Phase 2 study. Both companies see amylin drugs as either add-ons to existing GLP-1 therapy or alternatives for the millions of patients who don't get enough benefit from GLP-1s alone.

Novo Nordisk presented real-world data on September 30 at the European Association for the Study of Diabetes meeting in Milan. The data show that patients who switched from injectable obesity drugs to its oral Wegovy pill kept losing weight. The analysis was compiled with US telehealth company Ro and covered 194 patients who moved from injections, including Novo's own Wegovy and Eli Lilly's Zepbound, to oral semaglutide. Those patients lost an average of 4.1% of body weight, about 4 kg (8.8 lbs), over three months. Nearly 41% lost at least 5%, and the share classified as clinically obese fell from 87.1% to 65.5%. Real-world analyses show associations and cannot establish causality.

The data address a key question for the pill: whether patients stay on treatment once they move off injections. "Clearly, a lot of patients do even better on the pill than they did on the (injectable) drugs," Chief Scientific Officer Martin Holst Lange said, according to Reuters. The pill is on sale in the US, UK, Germany and UAE, with more launches planned. Novo says it accounts for about a third of US obesity prescriptions and more than 80% of new oral prescriptions. Novo is counting on the pill to win back ground after Eli Lilly overtook it as the obesity-drug market leader and its shares fell about 70% from their peak.

Novo Nordisk has signed a global licensing agreement worth up to $1.33 billion with Swedish drug-delivery company Nanexa, CNBC reported on September 25. The deal gives Novo exclusive rights to use Nanexa's PharmaShell technology in up to five development programs covering long-acting injectable drugs for obesity, type 2 diabetes and other cardiometabolic conditions. PharmaShell applies an ultra-thin inorganic coating to drug particles to control how they are released over time.

For the Wegovy maker, the deal is a formulation play, not a manufacturing or supply agreement. It gives Novo a route to injectables that could be dosed less often than today's weekly shots as it tries to defend its obesity franchise. It comes days after Novo's September 21 strategy update, where shares fell as investors questioned management on pricing and M&A. Nanexa's Stockholm-listed shares jumped more than 150% at the open before settling around 114% higher by late morning.

In a CNBC interview the day after Novo Nordisk's Capital Markets Day, CEO Mike Doustdar defended the company's diversification push and laid out a direct case for acquisitions. Doustdar said the company would actively seek out firms whose drugs can fill gaps it cannot close internally: "Let's see where the gaps are, and let's go out and see who has produced or is about to introduce better drugs than we are able to do on our own, and when that gap can be filled with M&A, we are actually quite interested about it." He acknowledged markets remained unconvinced by the Capital Markets Day plan, adding: "I think yesterday we laid out a more clear strategy of the direction we want to take the company at... but yet the reaction tells me that there's still some work to do in convincing some of the investors."

The CEO named blood and endocrine disorders, liver disease, and cardiovascular disease as the specific therapeutic areas where Novo intends to build out its portfolio alongside its GLP-1 franchise. The company's 2030 roadmap targets more than five "multi-blockbuster" drugs and over $23 billion in annual revenue by 2035 — a target investors have so far received coldly, with Novo shares down roughly 34% over the past year while rival Eli Lilly has gained around 54% in the same period.

Novo Nordisk shares fell as much as 7% on Monday after the Danish drugmaker presented a long-awaited strategy for sustaining growth beyond its blockbuster weight-loss drug Wegovy. The company pledged to launch more than five drugs with "multi-blockbuster" potential by 2030 and generate over 150 billion Danish kroner (approximately $23 billion) in pipeline sales by 2035 — targets investors found insufficient to offset the looming loss of semaglutide patent exclusivity in the United States starting in 2032.

CEO Mike Doustdar acknowledged the central challenge directly: "This loss of exclusivity is what's on most people's mind, and rightfully so," adding that Novo had "created an incredibly attractive market" now drawing competition from virtually every major pharmaceutical company. The competitive pressure is already visible in market share data: rival Eli Lilly held 60.9% of the combined obesity and diabetes drug market in Q2, compared with Novo's 38.8%. Shares settled roughly 5–6% lower by end of session.

Novo Nordisk discontinued two heart-failure studies for its experimental cardiovascular drug ziltivekimab in September 2026, following an independent data monitoring committee's determination that the trials had a "low likelihood" of succeeding after the drug failed a late-stage trial in July. That earlier study tested ziltivekimab's ability to reduce major adverse cardiovascular events, and the committee concluded the remaining heart-failure studies were unlikely to produce different outcomes. One trial testing the drug in post-heart-attack patients remains active, with results expected in the first half of 2027.

The cancellations deal a further blow to Novo Nordisk's efforts to diversify beyond its GLP-1 obesity and diabetes franchise at a time when competitive pressure from Eli Lilly is intensifying. The company launched oral Wegovy in January 2026 and surpassed two million prescriptions, but the ziltivekimab setbacks reduce near-term pipeline optionality. Hedge fund positioning reflects the divergence: as of Q2 2026, 59 funds held roughly $2 billion in NVO shares versus 152 funds holding $17.24 billion in Eli Lilly.

Novo Nordisk announced on September 14, 2026 that it will operate day-to-day under the simplified name "Novo," adopting the tagline "Lasting Health Starts Now" while retaining its legal name Novo Nordisk A/S globally. The rebrand preserves the company's heritage Apis bull logo in modernized form. CEO Mike Doustdar framed the move as a bid to make healthcare "more responsive, relevant and easier to fit into everyday life," reflecting shifting patient expectations amid intensifying competition from rivals such as Eli Lilly.

Alongside the visual refresh, the company unveiled a new cultural framework called "The Novo Way," built on four principles: customer obsession, competitiveness, clarity, and care & integrity. Executive Vice President Tania Sabroe said the cultural initiative is intended to "sharpen our competitive edge" by aligning brand perception with internal strategy. Novo Nordisk plans to provide detailed corporate strategy updates at a Capital Markets Day in London on September 21, 2026.

Novo Nordisk's STEP Young phase 3 trial delivered a striking result: 40.4% of children as young as six who received weekly semaglutide (Wegovy) for 68 weeks were no longer classified as obese, compared with 0% on placebo. A September 2026 Pediatrics journal study reinforced the demand backdrop, finding that GLP-1 prescribing among children aged 8–11 with obesity increased roughly 310-fold between 2019 and 2026—well ahead of any formal approval in that cohort.

The "bigger test," however, is commercial rather than clinical. Regulatory clearance, physician adoption, parental acceptance, and reimbursement coverage all stand between the trial data and revenue. That pressure is compounded by competitive dynamics: in the REDEFINE 4 trial, Novo's next-generation candidate CagriSema posted 23.0% weight loss versus 25.5% for Eli Lilly's tirzepatide, falling short of its non-inferiority endpoint and deepening questions about Novo's ability to field a credible successor to semaglutide. The pediatric program now represents one of the clearest near-term expansion levers for Novo while it works to close the pipeline gap with Lilly.

Morgan Stanley downgraded Novo Nordisk (NVO) to Sell on September 11, 2026, citing mounting competitive pressure from Eli Lilly in the obesity and diabetes market. The bank's survey data indicated Lilly is continuing to take share in the fast-growing GLP-1 segment, with Lilly's Zepbound capturing much of new Medicare demand through the GLP-1 Bridge program and a pipeline including Foundayo and experimental retatrutide set to intensify pressure from 2027 onward. Shares fell roughly 2% on the news.

Semaglutide — Novo Nordisk's core GLP-1 compound behind Wegovy and Ozempic — is expected to represent about 75% of 2026 sales but is projected to decline to 59% of the revenue mix by 2031 as patent expirations loom in the early-to-mid 2030s. Morgan Stanley views the narrowing of Novo Nordisk's pipeline advantage, combined with Lilly's strengthening formulary position, as a structural headwind that justifies a Sell rating.

Novo Nordisk has launched its oral Wegovy weight-loss pill in Germany, making it the first EU country where the pill-form GLP-1 treatment is available to consumers. Germany's position as the EU's largest pharmaceutical market lends the launch strategic weight, though a major constraint tempers the opportunity: German patients must currently pay for obesity treatments out of pocket, as public insurance does not cover them. Pharmacy pricing ranges from roughly €170 to €280 depending on dosage, limiting the addressable market compared to reimbursed settings. Despite that hurdle, Novo has reportedly secured approximately 90% market share in the oral obesity segment since launch, reflecting strong consumer appetite for a pill alternative to injections.

The Germany entry fits into a broader European GLP-1 buildout that Novo is executing ahead of intensifying competition. Eli Lilly's rival oral obesity drug Foundayo has already launched in the UK and is under regulatory review in more than 40 markets, with international expansion expected in 2027, giving Novo a narrow first-mover window in select EU countries. The company has estimated that oral GLP-1 treatments could account for over one-third of total GLP-1 usage by 2030. Weaker-than-expected early Wegovy pill sales and share losses to Lilly's injectable Zepbound in the US have kept investor expectations measured, making European market-access milestones like the German launch a key area of focus for the company's near-term growth narrative.